I Got Pregnant While Taking Semaglutide — What Happens Next

What UK and international regulators say about the risk

The Medicines and Healthcare products Regulatory Agency and the European Medicines Agency have both reviewed semaglutide's reproductive safety profile, and their conclusions are consistent: avoid use during pregnancy. The Wegovy Summary of Product Characteristics, published on the eMC, states that semaglutide should be discontinued at least two months before a planned pregnancy. This is not an arbitrary buffer, semaglutide has a half-life of roughly one week, meaning it takes several weeks to clear the body fully. The two-month window reflects that timeline with a margin of caution.

Animal studies showed that GLP-1 receptor agonists at doses comparable to those used therapeutically caused embryo-fetal developmental toxicity, including skeletal abnormalities and reduced fetal weight. Critically, these findings come from rodent and rabbit studies designed to detect hazard signals, not to replicate human physiology. The NHS medicines guidance for semaglutide confirms that the medicine is not recommended in pregnancy and advises stopping as soon as pregnancy is discovered.

No large, controlled human study has followed pregnant women who took semaglutide to term, partly because clinical trials routinely excluded pregnant participants, and partly because this situation, while not rare, is still being characterised through post-marketing pharmacovigilance. That absence of data cuts both ways: it does not prove safety, but it also means definitive human harm cannot currently be quantified from published evidence alone. Honest communication of that uncertainty matters.

What the semaglutide wash-out period means in practice

A question our prescribers hear most weeks from patients who are thinking about starting a family is: how long do I need to wait after stopping? The clinical answer, drawn from the Wegovy SmPC and NHS England's guidance on weight-management injections, is at least two months before trying to conceive. If you are already pregnant and want to understand whether you can be on semaglutide while pregnant, the short answer is no, the focus shifts entirely to stopping now and reporting the exposure.

Semaglutide's long half-life means even after the final dose, detectable levels persist for weeks. Early pregnancy, particularly the first trimester, is when organogenesis (the formation of organs) takes place, and this is the window most scrutinised in reproductive toxicity studies. Stopping quickly after a positive test reduces, though cannot eliminate, the duration of fetal exposure.

There is also a practical consideration around weight. Some people on Wegovy for conditions such as polycystic ovary syndrome may have become pregnant partly because weight loss improved their fertility. Stopping the medicine abruptly can lead to appetite returning; working with a dietitian or GP on nutritional support during pregnancy is sensible and worth raising at your first antenatal appointment.

Who to contact and what to tell them

Your first call should be to your GP. Tell them the name of the medicine (semaglutide, brand name Wegovy), your most recent dose, and the approximate date of your last injection. They will want to record the exposure and will likely refer you to your local maternity service for booking and, depending on local protocols, may flag the exposure for enhanced monitoring.

If you are currently accessing semaglutide through a regulated online pharmacy, contact that service too. At nume, our prescribers can be reached through our support line, and stopping treatment is straightforward, no penalty, no pressure. The prescription can be paused or cancelled the same day. Details of our clinical team and how prescriptions are managed are on our prescribers page.

You can also report your experience directly to the MHRA's Yellow Card scheme. Yellow Card captures real-world data on medicines used in pregnancy, and reports from patients contribute directly to the safety evidence base that regulators use to update guidance. It takes only a few minutes and is open to anyone, not just healthcare professionals.

What happens after you stop, and what is still uncertain

Most people who have stopped semaglutide promptly on discovering a pregnancy go on to have straightforward pregnancies. The early-exposure data that does exist, largely from spontaneous reports and a small number of case series, has not consistently shown a pattern of specific pregnancy complications attributable to semaglutide. That is cautiously reassuring, but it is not the same as a clean bill of safety, and if you want a fuller picture of whether you can take semaglutide while pregnant, the guidance remains firm: avoid it, because the uncertainty itself is the reason for caution. The honest answer is that more research is needed, and that position stands.

For more on the broader question of Wegovy and pregnancy planning, including contraception advice while on treatment and returning to semaglutide after delivery, those questions are worth exploring with your GP or the clinical team that manages your weight-care. If you had been weighing up starting Wegovy before discovering the pregnancy, that conversation will need to wait until after you have delivered and, if you are breastfeeding, until you have finished feeding, and our guidance on drinking alcohol while taking semaglutide is similarly worth revisiting once treatment resumes at the right time after delivery.

Once your pregnancy is established and you are ready to think about longer-term weight management again, the range of options available through a clinically supervised private service can be revisited with your prescriber at the right time.